^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SND1-BRAF fusion

    i
    Other names: SND1, Staphylococcal Nuclease And Tudor Domain Containing 1, TDRD11, P100, Staphylococcal Nuclease Domain-Containing Protein 1, Tudor Domain-Containing Protein 11, EBNA2 Coactivator P100, Tudor-SN, Testis Tissue Sperm-Binding Protein Li 82P, P100 EBNA2 Co-Activator, 100 KDa Coactivator, P100 Co-Activator, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673; 27044
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    almost2years
    Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC). (ASCO-GU 2023)
    Activating BRAF alterations are detected in ~3% of aPC, with frequent BRAF-SND1 fusions. BRAF RE represent almost half of aPC BRAF GA, the highest fraction observed across a pan-tumor dataset. In addition, we detected a higher incidence of concurrent CDK12 GA and a lower relative frequency of concurrent PTEN,APC, and TMPRSS2-ERG GA.
    Metastases
    |
    BRAF (B-raf proto-oncogene) • PTEN (Phosphatase and tensin homolog) • CDK12 (Cyclin dependent kinase 12) • ERG (ETS Transcription Factor ERG)
    |
    BRAF V600E • BRAF V600 • PTEN mutation • BRAF wild-type • CDK12 mutation • BRAF fusion • BRAF K601E • BRAF G469A • TMPRSS2-ERG fusion • SND1-BRAF fusion • BRAF K601
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx
    2years
    MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer. (PubMed, Clin Transl Oncol)
    Our study describes the patient-driven discovery of the first BRAF fusion-driven prostate cancer effectively treated with trametinib. Consequently, MAPK pathway activation could define a new subtype of prostate cancer susceptible to a tailored management.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF fusion • SND1-BRAF fusion
    |
    Mekinist (trametinib)